Aduro Biotech to Host Investor Event Featuring ADU-S100 (MIW815) Clinical Data Presented at the 2019 American Society of Clinical Oncology Annual Meeting
May 15, 2019 at 17:06 PM EDT
BERKELEY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the company will host and webcast an investor event on Monday, June 3, 2019 at 6:30 am CDT in Chicago, IL. Guest speaker, Dr. Funda Meric-Bernstam of MD Anderson Cancer Center, is a principal investigator for the Phase 1 study of STING pathway activator ADU-S100 (MIW815) in combination with spartalizumab (PDR001), Novartis’ investigational anti-PD-1 monoclonal antibody, in patients with advanced/metastatic solid tumors or lymphomas.
To access the live webcast and subsequent archived recording of this and other company presentations, please visit the investor section of Aduro's website at www.aduro.com. The archived webcast will remain available for replay on Aduro’s website for 30 days.
Details of the ADU-S100 (MIW815) ASCO oral presentation are as follows:
To view this and other Aduro abstracts, please visit the ASCO website located at http://abstracts.asco.org/.
Cautionary Note on Forward-Looking Statements